🔎 Trials Near Me

Home › Cancer (all types) › Georgia › Athens

Cancer (all types) clinical trials in Athens, GA

5 studies for Cancer (all types) are looking for participants at sites in and around Athens (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

RecruitingPhase 3
  • University Cancer & Blood Center, LLC, Athens
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

RecruitingPhase 2
  • University Cancer & Blood Center (UCBC) - Athens, Athens
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06010329

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

RecruitingPhase 2
  • University Cancer & Blood Center, Athens
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT05168566

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

RecruitingPhase 2/3
  • University Cancer & Blood Center, LLC, Athens
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06989437

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

RecruitingPhase 1/2
  • University Cancer and Blood Center, Athens
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116

About Cancer (all types)

If you or someone you love has been diagnosed with cancer, learn about diagnosis, treatment, risk factors, coping and much more.

More about Cancer (all types) on MedlinePlus

Cancer (all types) trials in other cities

Other studies in Athens

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.